Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma

Secretory clusterin (sCLU) is expressed in numerous cancers and is associated with the resistance to chemotherapy. However, the role of sCLU in the resistance of hepatocellular carcinoma (HCC) to oxaliplatin (OXA), a recently used third‐generation platinum agent, remains unclear. The stable transfec...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Cancer Sci
Egile Nagusiak: Xiu, Peng, Dong, Xuesong, Dong, Xiaofeng, Xu, Zongzhen, Zhu, Huaqiang, Liu, Feng, Wei, Zheng, Zhai, Bo, Kanwar, Jagat R., Jiang, Hongchi, Li, Jie, Sun, Xueying
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: John Wiley and Sons Inc. 2013
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC7657244/
https://ncbi.nlm.nih.gov/pubmed/23279642
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/cas.12088
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak